董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Boyd | 男 | Director | 39 | 未披露 | 未持股 | 2020-03-02 |
| Jeffrey A. Chodakewitz | 男 | Director | 64 | 5.75万美元 | 6.50 | 2020-03-02 |
| Leonard Patrick Gage | 男 | Chairman of the Board | 77 | 10.00万美元 | 未持股 | 2020-03-02 |
| Larry Edwards | 男 | President, Chief Executive Officer and Director | 48 | 80.95万美元 | 未持股 | 2020-03-02 |
| Jeffrey Chodakewitz | 男 | Director | 64 | 未披露 | 未持股 | 2020-03-02 |
| John Freund | 男 | Director | 66 | 未披露 | 未持股 | 2020-03-02 |
| Keith Maher | 男 | Director | 51 | 未披露 | 未持股 | 2020-03-02 |
| John G. Freund | 男 | Director | 66 | 6.50万美元 | 37.57 | 2020-03-02 |
| Guy Macdonald | 男 | Director | 61 | 114.50万美元 | 134.95 | 2020-03-02 |
| Garen Bohlin | 男 | Director | 72 | 7.00万美元 | 10.76 | 2020-03-02 |
| Gerri Henwood | 女 | Director | 67 | 5.75万美元 | 5.50 | 2020-03-02 |
| Nancy Wysenski | 女 | Director | 62 | 6.50万美元 | 6.50 | 2020-03-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Maria Stahl | 女 | Chief Business Officer and General Counsel | 49 | 68.64万美元 | 未持股 | 2020-03-02 |
| Christopher Watt | 男 | Senior Vice President, Finance | 55 | 48.54万美元 | 未持股 | 2020-03-02 |
| Larry Edwards | 男 | President, Chief Executive Officer and Director | 48 | 80.95万美元 | 未持股 | 2020-03-02 |
董事简历
中英对照 | 中文 | 英文- Steven Boyd
-
Steven Boyd，自本公司2014年2月的私募发行之时起，就担任Reverse Mortgage Investment Trust Inc的董事。2010年5月起，他担任BlueMountain Capital Management, LLC的投资组合经理，领导住宅按揭团队，管理着多项投资业务，涉及非机构抵押贷款支持证券、机构信用风险交易、与抵押贷款公司的战略伙伴关系。2005年3月至2009年11月，他是Citadel Investment Group的投资组合经理，曾是全球证券化产品团队的一员；任职期间，他在整个2008年信贷风险时期，管理着长/短期、不良抵押产品的策略，并实施了一些著名的交易，其中包括金融服务公司E Trade Financial Corporation、按揭发起及特别服务商ResMAE Mortgage Corp的收购。
Steven Boyd has served as a director since July 2020. Mr. Boyd has served since 2012 as the chief investment officer of Armistice Capital, LLC "Armistice", a long-short equity hedge fund focused on the health care and consumer sectors. From 2005 to 2012 Mr. Boyd was a research analyst at Senator Investment Group, York Capital and SAB Capital Management, where he focused on health care. Mr. Boyd began his career as an analyst at McKinsey & Company. Mr. Boyd currently serves as a member of the boards of directors of Aytu BioScience, Inc., Cerecor Inc. and EyeGate Pharmaceuticals, Inc. Mr. Boyd received a B.S. in economics and a B.A. in political science from The Wharton School of the University of Pennsylvania. - Steven Boyd，自本公司2014年2月的私募发行之时起，就担任Reverse Mortgage Investment Trust Inc的董事。2010年5月起，他担任BlueMountain Capital Management, LLC的投资组合经理，领导住宅按揭团队，管理着多项投资业务，涉及非机构抵押贷款支持证券、机构信用风险交易、与抵押贷款公司的战略伙伴关系。2005年3月至2009年11月，他是Citadel Investment Group的投资组合经理，曾是全球证券化产品团队的一员；任职期间，他在整个2008年信贷风险时期，管理着长/短期、不良抵押产品的策略，并实施了一些著名的交易，其中包括金融服务公司E Trade Financial Corporation、按揭发起及特别服务商ResMAE Mortgage Corp的收购。
- Steven Boyd has served as a director since July 2020. Mr. Boyd has served since 2012 as the chief investment officer of Armistice Capital, LLC "Armistice", a long-short equity hedge fund focused on the health care and consumer sectors. From 2005 to 2012 Mr. Boyd was a research analyst at Senator Investment Group, York Capital and SAB Capital Management, where he focused on health care. Mr. Boyd began his career as an analyst at McKinsey & Company. Mr. Boyd currently serves as a member of the boards of directors of Aytu BioScience, Inc., Cerecor Inc. and EyeGate Pharmaceuticals, Inc. Mr. Boyd received a B.S. in economics and a B.A. in political science from The Wharton School of the University of Pennsylvania.
- Jeffrey A. Chodakewitz
-
Jeffrey A. Chodakewitz，他是Vertex Pharmaceuticals Incorporated的执行副总裁，负责全球药品开发和医疗事务，也曾担任首席医疗官。他于2014年1月加入Vertex公司，担任高级副总裁，并于2014年10月成为执行副总裁。加入Vertex Pharmaceuticals Incorporated之前，他曾任职Merck & Co.20年以上，在那里他曾担任多种职务，包括临床研究、传染性疾病和疫苗副总裁、临床药理学/早期发展副总裁、生育后期高级副总裁、负责全球科学战略传染病、呼吸/免疫学的高级副总裁。任职Merck公司之前，他曾担任the Veterans Administration Medical Center （位于美国康乃迪克州西黑文）的艾滋病门诊的董事，也曾担任Yale University、New York University Schools of Medicine的多种学术职务。他还担任Tetraphase Pharmaceuticals公司（一个制药公司）的董事会成员。他持有Yale University的生物化学学士学位，以及the Yale University School of Medicine的医学博士学位。
Jeffrey A. Chodakewitz is Vertex Pharmaceuticals Incorporated Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer. Dr. Chodakewitz joined Vertex as a Senior Vice President in January 2014 and became an Executive Vice President in October 2014. Prior to joining Vertex Pharmaceuticals Incorporated, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research - Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy Infectious Diseases, Respiratory/Immunology. Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut and held various academic positions at Yale University and New York University Schools of Medicine. Dr. Chodakewitz serves as a member of the Board of Directors of Tetraphase Pharmaceuticals, Inc., a pharmaceutical company. Dr. Chodakewitz holds B.S. in Biochemistry from Yale University, and an M.D. from the Yale University School of Medicine. - Jeffrey A. Chodakewitz，他是Vertex Pharmaceuticals Incorporated的执行副总裁，负责全球药品开发和医疗事务，也曾担任首席医疗官。他于2014年1月加入Vertex公司，担任高级副总裁，并于2014年10月成为执行副总裁。加入Vertex Pharmaceuticals Incorporated之前，他曾任职Merck & Co.20年以上，在那里他曾担任多种职务，包括临床研究、传染性疾病和疫苗副总裁、临床药理学/早期发展副总裁、生育后期高级副总裁、负责全球科学战略传染病、呼吸/免疫学的高级副总裁。任职Merck公司之前，他曾担任the Veterans Administration Medical Center （位于美国康乃迪克州西黑文）的艾滋病门诊的董事，也曾担任Yale University、New York University Schools of Medicine的多种学术职务。他还担任Tetraphase Pharmaceuticals公司（一个制药公司）的董事会成员。他持有Yale University的生物化学学士学位，以及the Yale University School of Medicine的医学博士学位。
- Jeffrey A. Chodakewitz is Vertex Pharmaceuticals Incorporated Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer. Dr. Chodakewitz joined Vertex as a Senior Vice President in January 2014 and became an Executive Vice President in October 2014. Prior to joining Vertex Pharmaceuticals Incorporated, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research - Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy Infectious Diseases, Respiratory/Immunology. Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut and held various academic positions at Yale University and New York University Schools of Medicine. Dr. Chodakewitz serves as a member of the Board of Directors of Tetraphase Pharmaceuticals, Inc., a pharmaceutical company. Dr. Chodakewitz holds B.S. in Biochemistry from Yale University, and an M.D. from the Yale University School of Medicine.
- Leonard Patrick Gage
-
Leonard Patrick Gage自2011年12月以来担任我们的董事会成员和董事会主席。自2002年7月起，Gage博士担任生物制药行业的顾问。从1998年到2002年，Gage博士担任惠氏研究公司（Wyeth Research）的总裁，现在是辉瑞公司（Pfizer，Inc.）的一部分。在加入Wyeth Research之前，他从1989年到1998年在Genetics Institute，Inc.（一家公开上市的生物技术公司）担任多个职位，首先担任研究与开发主管，然后担任首席运营官，最后担任总裁。1971年至1989年，Gage博士曾在Hoffmann-La Roche Inc.（一家制药公司）担任多个研究管理职位，最近担任负责美国药物发现的Vice President。Gage博士自2009年11月以来一直担任Cytokinetics，Incorporated（一家公开上市的生物制药公司）的董事会成员，并自2010年3月以来担任其董事会主席。此前，他曾于2003年至2008年担任PDLBioPharma，Inc.（一家上市生物技术公司）的董事会成员，2007年担任其董事会主席，2007年至2008年担任其临时首席执行官。Gage博士目前在海洋生物实验室（Marine Biological Laboratories）董事会任职。Gage博士在麻省理工学院（Massachusetts Institute of Technology）获得物理学学士学位，在芝加哥大学（University of Chicago）获得生物物理学博士学位。
Leonard Patrick Gage has served as a member of our board of directors and as Chairman of our board of directors since December 2011. Since July 2002 Dr. Gage has served as a consultant to the biopharmaceutical industry. From 1998 to 2002 Dr. Gage served as President of Wyeth Research now part of Pfizer, Inc.. Prior to joining Wyeth Research, he served in various positions at Genetics Institute, Inc., a publicly traded biotechnology company, from 1989 to 1998 first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989 Dr. Gage served in various positions in research management with Hoffmann-La Roche Inc., a pharmaceutical company, most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served on the board of directors of Cytokinetics, Incorporated, a publicly traded biopharmaceuticals company, since November 2009 and as Chairman of its board of directors since March 2010. Previously he served on the board of directors of PDL BioPharma, Inc., a publicly traded biotechnology company, from 2003 through 2008 as the Chairman of its board of directors in 2007 and as its Interim Chief Executive Officer from 2007 to 2008. Dr. Gage currently serves on the board of directors of Marine Biological Laboratories. Dr. Gage received an S.B. in physics from the Massachusetts Institute of Technology and a Ph.D. in biophysics from the University of Chicago. - Leonard Patrick Gage自2011年12月以来担任我们的董事会成员和董事会主席。自2002年7月起，Gage博士担任生物制药行业的顾问。从1998年到2002年，Gage博士担任惠氏研究公司（Wyeth Research）的总裁，现在是辉瑞公司（Pfizer，Inc.）的一部分。在加入Wyeth Research之前，他从1989年到1998年在Genetics Institute，Inc.（一家公开上市的生物技术公司）担任多个职位，首先担任研究与开发主管，然后担任首席运营官，最后担任总裁。1971年至1989年，Gage博士曾在Hoffmann-La Roche Inc.（一家制药公司）担任多个研究管理职位，最近担任负责美国药物发现的Vice President。Gage博士自2009年11月以来一直担任Cytokinetics，Incorporated（一家公开上市的生物制药公司）的董事会成员，并自2010年3月以来担任其董事会主席。此前，他曾于2003年至2008年担任PDLBioPharma，Inc.（一家上市生物技术公司）的董事会成员，2007年担任其董事会主席，2007年至2008年担任其临时首席执行官。Gage博士目前在海洋生物实验室（Marine Biological Laboratories）董事会任职。Gage博士在麻省理工学院（Massachusetts Institute of Technology）获得物理学学士学位，在芝加哥大学（University of Chicago）获得生物物理学博士学位。
- Leonard Patrick Gage has served as a member of our board of directors and as Chairman of our board of directors since December 2011. Since July 2002 Dr. Gage has served as a consultant to the biopharmaceutical industry. From 1998 to 2002 Dr. Gage served as President of Wyeth Research now part of Pfizer, Inc.. Prior to joining Wyeth Research, he served in various positions at Genetics Institute, Inc., a publicly traded biotechnology company, from 1989 to 1998 first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989 Dr. Gage served in various positions in research management with Hoffmann-La Roche Inc., a pharmaceutical company, most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served on the board of directors of Cytokinetics, Incorporated, a publicly traded biopharmaceuticals company, since November 2009 and as Chairman of its board of directors since March 2010. Previously he served on the board of directors of PDL BioPharma, Inc., a publicly traded biotechnology company, from 2003 through 2008 as the Chairman of its board of directors in 2007 and as its Interim Chief Executive Officer from 2007 to 2008. Dr. Gage currently serves on the board of directors of Marine Biological Laboratories. Dr. Gage received an S.B. in physics from the Massachusetts Institute of Technology and a Ph.D. in biophysics from the University of Chicago.
- Larry Edwards
-
Larry Edwards，他一直担任董事、总裁和首席执行官（2020年以来）。从2015年到2020年，他担任Tetraphase Pharmaceuticals, Inc.的多个职位，最近担任首席执行官。从2014年到2015年，他担任Cubist Pharmaceuticals, Inc.（被Merck & Co.， Inc.收购）的革兰氏阴性特许经营权的高级营销总监。从1999年到2014年，他曾担任Merck and Co.,Inc.的多个职位，最近担任艰难梭菌和新传染病产品的全球营销总监。他获得俄亥俄大学（Ohio University）的商业和医疗管理学士学位。
Larry Edwards has served as a director, President and Chief Executive Officer since 2020. From 2015 to 2020 he served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015 Mr. Edwards served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc.. From 1999 to 2014 he served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University. - Larry Edwards，他一直担任董事、总裁和首席执行官（2020年以来）。从2015年到2020年，他担任Tetraphase Pharmaceuticals, Inc.的多个职位，最近担任首席执行官。从2014年到2015年，他担任Cubist Pharmaceuticals, Inc.（被Merck & Co.， Inc.收购）的革兰氏阴性特许经营权的高级营销总监。从1999年到2014年，他曾担任Merck and Co.,Inc.的多个职位，最近担任艰难梭菌和新传染病产品的全球营销总监。他获得俄亥俄大学（Ohio University）的商业和医疗管理学士学位。
- Larry Edwards has served as a director, President and Chief Executive Officer since 2020. From 2015 to 2020 he served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015 Mr. Edwards served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc.. From 1999 to 2014 he served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.
- Jeffrey Chodakewitz
-
暂无中文简介
Jeffrey Chodakewitz has served as a member of our board of directors since June 2014. Dr. Chodakewitz currently serves as a senior advisor to Blackstone Life Sciences, a life sciences fund. From April 2018 to March 2019 Dr. Chodakewitz served as Executive Vice President, Clinical Medicine and External Innovation of Vertex Pharmaceuticals Incorporated, a publicly traded pharmaceutical company. From October 2014 to March 2018 Dr. Chodakewitz served as Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer of Vertex. From January 2014 to October 2014 Dr. Chodakewitz served as Senior Vice President and Chief Medical Officer of Vertex. Prior to joining Vertex, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research-Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy Infectious Diseases, Respiratory/Immunology. Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut, and held various academic positions at Yale University and New York University Schools of Medicine. Dr. Chodakewitz serves on the board of directors of resTORbio, Inc., a publicly traded biopharmaceutical company focused on age-related diseases. Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine (both Internal Medicine and Infectious Diseases). He received a B.S. in Biochemistry from Yale University, cum laude, and an M.D. from the Yale University School of Medicine. We believe that Dr. Chodakewitz’s scientific, medical and business background allows him to be a key contributor to our board of directors. -
暂无中文简介
- Jeffrey Chodakewitz has served as a member of our board of directors since June 2014. Dr. Chodakewitz currently serves as a senior advisor to Blackstone Life Sciences, a life sciences fund. From April 2018 to March 2019 Dr. Chodakewitz served as Executive Vice President, Clinical Medicine and External Innovation of Vertex Pharmaceuticals Incorporated, a publicly traded pharmaceutical company. From October 2014 to March 2018 Dr. Chodakewitz served as Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer of Vertex. From January 2014 to October 2014 Dr. Chodakewitz served as Senior Vice President and Chief Medical Officer of Vertex. Prior to joining Vertex, Dr. Chodakewitz spent more than 20 years at Merck & Co., Inc., where he held a variety of roles including Vice President of Clinical Research-Infectious Diseases & Vaccines, Vice President of Clinical Pharmacology/Early Stage Development, Senior Vice President of Late Stage Development, and Senior Vice President of Global Scientific Strategy Infectious Diseases, Respiratory/Immunology. Prior to his tenure at Merck, he served as the Director of the HIV Outpatient Clinic at the Veterans Administration Medical Center in West Haven, Connecticut, and held various academic positions at Yale University and New York University Schools of Medicine. Dr. Chodakewitz serves on the board of directors of resTORbio, Inc., a publicly traded biopharmaceutical company focused on age-related diseases. Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine (both Internal Medicine and Infectious Diseases). He received a B.S. in Biochemistry from Yale University, cum laude, and an M.D. from the Yale University School of Medicine. We believe that Dr. Chodakewitz’s scientific, medical and business background allows him to be a key contributor to our board of directors.
- John Freund
-
暂无中文简介
John Freund has served as a member of our board of directors since October 2012. Dr. Freund founded Skyline Ventures, a venture capital firm, in 1997 and has served as a managing director at Skyline since its founding. He is also co-founder, director and chief executive officer of Arixa Pharmaceuticals, Inc., a privately held antibiotic company. Prior to founding Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995 he co-founded Intuitive Surgical, Inc. a medical device company, and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the board of directors of Collegium Pharmaceutical, Inc., a publicly traded biotechnology company, since 2014; SI-BONE, Inc., a publicly traded medical device company, since 2012; and Sutro Biopharma, Inc., a publicly traded biotechnology company, since 2014. Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by Capital Research and Management. He also previously served on the board of directors of a number of publicly traded companies, including Proteon Therapeutics, Inc., a publicly traded biotechnology company; XenoPort, Inc., a biopharmaceutical company, where he served as chairman of the board; Map Pharmaceuticals, Inc. a biopharmaceutical company; Hansen Medical, Inc., a medical device company; Mako Surgical Corp., a medical device company; and Concert Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School. We believe that Dr. Freund’s extensive investment experience, his experience as an executive and his service on the board of directors of numerous public and privately held companies allows him to be a key contributor to our board of directors. -
暂无中文简介
- John Freund has served as a member of our board of directors since October 2012. Dr. Freund founded Skyline Ventures, a venture capital firm, in 1997 and has served as a managing director at Skyline since its founding. He is also co-founder, director and chief executive officer of Arixa Pharmaceuticals, Inc., a privately held antibiotic company. Prior to founding Skyline, Dr. Freund served as managing director in the private equity group of Chancellor Capital Management, a private capital investment firm. In 1995 he co-founded Intuitive Surgical, Inc. a medical device company, and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation, a maker of ultrasound equipment that is now part of Siemens, most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a general partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund was at Morgan Stanley & Co., an investment banking company, where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. He has served on the board of directors of Collegium Pharmaceutical, Inc., a publicly traded biotechnology company, since 2014; SI-BONE, Inc., a publicly traded medical device company, since 2012; and Sutro Biopharma, Inc., a publicly traded biotechnology company, since 2014. Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by Capital Research and Management. He also previously served on the board of directors of a number of publicly traded companies, including Proteon Therapeutics, Inc., a publicly traded biotechnology company; XenoPort, Inc., a biopharmaceutical company, where he served as chairman of the board; Map Pharmaceuticals, Inc. a biopharmaceutical company; Hansen Medical, Inc., a medical device company; Mako Surgical Corp., a medical device company; and Concert Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund received a B.A. in history from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School. We believe that Dr. Freund’s extensive investment experience, his experience as an executive and his service on the board of directors of numerous public and privately held companies allows him to be a key contributor to our board of directors.
- Keith Maher
-
Keith Maher自2019年以来一直担任Armistice Capital，LLC的董事总经理。从2007年到2018年，Maher博士在施罗德投资管理公司，欧米茄顾问公司和Gracie Capital担任高级职务。Maher博士是从Valesco梦百合Partners公司加入Gracie公司的，该公司是他与Paramount Bio Capital公司合作创立的一家全球梦百合基金。在创立Valesco之前，Maher博士是Weiss，Peck&Greer WPG Investments的常务董事。他从雷曼兄弟（Lehman Brothers）加入WPG，在那里他担任股票研究分析师，涵盖医疗设备和技术公司。Maher博士目前在EyegatePharmaceuticals，Inc.和Vaxart，Inc.的董事会任职。Maher博士在波士顿大学（Boston University）获得生物学学士学位，在西北大学（Northwestern University）凯洛格管理研究生院（Kellogg Graduate School of Management）获得工商管理硕士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位。Maher博士在医学部西奈山医疗中心（Mount Sinai Medical Center）完成了他的临床培训。
Keith Maher has served as a director since July 2020. Dr. Maher has served as a managing director at Armistice since 2019. From 2007 to 2018 Dr. Maher held senior roles at Schroder Investment Management, Omega Advisors and Gracie Capital. Dr. Maher joined Gracie from Valesco Healthcare Partners, a global healthcare fund he founded in partnership with Paramount Bio Capital. Prior to starting Valesco, Dr. Maher was a managing director at Weiss, Peck & Greer Investments “WPG”. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher currently serves on the board EyeGate Pharmaceuticals, Inc. Dr. Maher received a B.A. in biology from Boston University, an M.B.A. from Northwestern University's Kellogg Graduate School of Management and an M.D. from Albany Medical College. Dr. Maher completed his clinical training at the Mount Sinai Medical Center in the Department of Medicine. - Keith Maher自2019年以来一直担任Armistice Capital，LLC的董事总经理。从2007年到2018年，Maher博士在施罗德投资管理公司，欧米茄顾问公司和Gracie Capital担任高级职务。Maher博士是从Valesco梦百合Partners公司加入Gracie公司的，该公司是他与Paramount Bio Capital公司合作创立的一家全球梦百合基金。在创立Valesco之前，Maher博士是Weiss，Peck&Greer WPG Investments的常务董事。他从雷曼兄弟（Lehman Brothers）加入WPG，在那里他担任股票研究分析师，涵盖医疗设备和技术公司。Maher博士目前在EyegatePharmaceuticals，Inc.和Vaxart，Inc.的董事会任职。Maher博士在波士顿大学（Boston University）获得生物学学士学位，在西北大学（Northwestern University）凯洛格管理研究生院（Kellogg Graduate School of Management）获得工商管理硕士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位。Maher博士在医学部西奈山医疗中心（Mount Sinai Medical Center）完成了他的临床培训。
- Keith Maher has served as a director since July 2020. Dr. Maher has served as a managing director at Armistice since 2019. From 2007 to 2018 Dr. Maher held senior roles at Schroder Investment Management, Omega Advisors and Gracie Capital. Dr. Maher joined Gracie from Valesco Healthcare Partners, a global healthcare fund he founded in partnership with Paramount Bio Capital. Prior to starting Valesco, Dr. Maher was a managing director at Weiss, Peck & Greer Investments “WPG”. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher currently serves on the board EyeGate Pharmaceuticals, Inc. Dr. Maher received a B.A. in biology from Boston University, an M.B.A. from Northwestern University's Kellogg Graduate School of Management and an M.D. from Albany Medical College. Dr. Maher completed his clinical training at the Mount Sinai Medical Center in the Department of Medicine.
- John G. Freund
-
John G. Freund于1997年创立了Skyline Ventures（“Skyline”），这是一家风险投资公司，自成立以来一直担任Skyline的董事总经理。在加入Skyline之前，他曾担任Chancellor Capital Management， LLC的私募股权集团的董事总经理。1995年，他共同创立了Intuitive Surgical， Inc.，并在其董事会任职至2000年。从1988年到1994年，他在Acuson Corporation（“Acuson”）担任多个职位，最近担任执行副总裁。加入Acuson之前，1987年至1988年，他是Morgan Stanley Venture Partners的普通合伙人。1982年至1988年，他在Morgan Stanley & Co.工作，并于1983年共同创立了公司财务部的医疗保健集团。他目前担任Tetraphase Pharmaceuticals， Inc.（纳斯达克股票代码：TTPH）（2012年至今）和Proteon Therapeutics， Inc.（纳斯达克股票代码：PRTO）（2014年至今）的董事会成员，以及两家私人控股公司Sutro Biopharma， Inc.（2014年至今）和SI-Bone， Inc.（2013年至今）的董事会成员。他还担任the Capital Group Companies管理的六个美国注册投资基金的董事会成员。此前，他曾担任几家上市公司的董事会成员，包括XenoPort， Inc.（纳斯达克股票代码：XNPT）（1999年至2016年），在那里他担任Concert Pharmaceuticals， Inc.（纳斯达克股票代码：CNCE）（2014年至2015年），MAP Pharmaceuticals, Inc.（纳斯达克股票代码：MAPP）（2004年至2011年）和MAKO Surgical Corp.（纳斯达克股票代码：MAKO）（2008年至2013年）的董事长。他是哈佛商学院医疗保健倡议咨询委员会的成员。他于1975年毕业于哈佛大学，获得历史学士学位，1980年获得哈佛医学院（Harvard Medical School）医学博士学位，1982年获得哈佛商学院（Harvard Business School）工商管理硕士学位。
John G. Freund founded Skyline Ventures "Skyline", a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation ("Acuson"), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982. - John G. Freund于1997年创立了Skyline Ventures（“Skyline”），这是一家风险投资公司，自成立以来一直担任Skyline的董事总经理。在加入Skyline之前，他曾担任Chancellor Capital Management， LLC的私募股权集团的董事总经理。1995年，他共同创立了Intuitive Surgical， Inc.，并在其董事会任职至2000年。从1988年到1994年，他在Acuson Corporation（“Acuson”）担任多个职位，最近担任执行副总裁。加入Acuson之前，1987年至1988年，他是Morgan Stanley Venture Partners的普通合伙人。1982年至1988年，他在Morgan Stanley & Co.工作，并于1983年共同创立了公司财务部的医疗保健集团。他目前担任Tetraphase Pharmaceuticals， Inc.（纳斯达克股票代码：TTPH）（2012年至今）和Proteon Therapeutics， Inc.（纳斯达克股票代码：PRTO）（2014年至今）的董事会成员，以及两家私人控股公司Sutro Biopharma， Inc.（2014年至今）和SI-Bone， Inc.（2013年至今）的董事会成员。他还担任the Capital Group Companies管理的六个美国注册投资基金的董事会成员。此前，他曾担任几家上市公司的董事会成员，包括XenoPort， Inc.（纳斯达克股票代码：XNPT）（1999年至2016年），在那里他担任Concert Pharmaceuticals， Inc.（纳斯达克股票代码：CNCE）（2014年至2015年），MAP Pharmaceuticals, Inc.（纳斯达克股票代码：MAPP）（2004年至2011年）和MAKO Surgical Corp.（纳斯达克股票代码：MAKO）（2008年至2013年）的董事长。他是哈佛商学院医疗保健倡议咨询委员会的成员。他于1975年毕业于哈佛大学，获得历史学士学位，1980年获得哈佛医学院（Harvard Medical School）医学博士学位，1982年获得哈佛商学院（Harvard Business School）工商管理硕士学位。
- John G. Freund founded Skyline Ventures "Skyline", a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation ("Acuson"), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982.
- Guy Macdonald
-
Guy Macdonald，2008年1月起，他担任Scynexis, Inc.总裁、首席执行官和董事会成员。2003年8月至2008年1月，他担任生物制药公司艾德尼克斯制药有限公司（Idenix Pharmaceuticals, Inc.）的运营执行副总裁。加入Idenix之前，1981至2003年，他在制药公司默克公司（Merck & Co., Inc.）担任多职，最近担任抗感染和医院产品副总裁。他目前是私营公司Spring Bank Pharmaceuticals, Inc.的董事会主席。他在苏格兰邓迪大学（Dundee University）获得生物化学荣誉学位。
Guy Macdonald,has served as a member of Scynexis, Inc. Board since November 2014. Mr. Macdonald served as a member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a publicly-traded biopharmaceutical company, from January 2008 to July 2020, in addition to serving as its President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc., most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland. - Guy Macdonald，2008年1月起，他担任Scynexis, Inc.总裁、首席执行官和董事会成员。2003年8月至2008年1月，他担任生物制药公司艾德尼克斯制药有限公司（Idenix Pharmaceuticals, Inc.）的运营执行副总裁。加入Idenix之前，1981至2003年，他在制药公司默克公司（Merck & Co., Inc.）担任多职，最近担任抗感染和医院产品副总裁。他目前是私营公司Spring Bank Pharmaceuticals, Inc.的董事会主席。他在苏格兰邓迪大学（Dundee University）获得生物化学荣誉学位。
- Guy Macdonald,has served as a member of Scynexis, Inc. Board since November 2014. Mr. Macdonald served as a member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a publicly-traded biopharmaceutical company, from January 2008 to July 2020, in addition to serving as its President and Chief Executive Officer from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc., a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc., most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland.
- Garen Bohlin
-
Garen Bohlin，2010年7月起，他担任我公司董事会成员。2012年5月起，他担任生命科学公司的顾问。2010年1月至2012年4月，他担任生物制药公司Constellation Pharmaceuticals, Inc.的执行副总裁。加入Constellation Pharmaceuticals之前，2005至2009年12月，他担任生物制药公司Sirtris Pharmaceuticals的首席运营官。1999至2008年12月，他担任生物制药公司Syntonix Pharmaceuticals, Inc.的创始首席执行官。在他职业生涯早期，他在生物技术公司Genetics Institute担任多个执行官职位并且是公共会计与咨询公司Arthur Andersen & Co。的合伙人。2005年起，他担任私人生物技术公司Acusphere, Inc.的董事会成员， 该公司曾是上市公司。他目前是私人公司Precision Dermatology, Inc.和上市公司Karyopharm Therapeutics, Inc.的董事会成员。2005至2007年，他担任生物制药公司Praecis Pharmaceuticals, Inc.的董事会成员，该公司曾是上市公司，现在属于葛兰素史克（GlaxoSmithKline）；2007至2009年，担任Targanta Therapeutics, Inc.的董事会成员，该公司曾是上市生物制药公司，现在属于The Medicines Company；2010至2013年担任私人公司SpringLeaf Therapeutics, Inc.的董事会成员。他在伊利诺伊大学（The University of Illinois）获得会计学和金融系学士学位。
Garen Bohlin has served as a member of our board of directors since July 2010. Since May 2012 Mr. Bohlin has served on the boards of directors and as a consultant to multiple life sciences companies. From January 2010 until April 2012 he served as Executive Vice President of Constellation Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., a biotechnology company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biotechnology company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Collegium Pharmaceutical, Inc. and Karyopharm Therapeutics, Inc., both publicly traded biotechnology companies. He also served on the board of directors for Acusphere, Inc., a specialty pharmaceutical company that was a publicly traded company, from 2005 to 2014; SpringLeaf Therapeutics, Inc., a private biotechnology company, from 2010 to 2013; Precision Dermatology, Inc., a private dermatology company from 2012 to 2014; and Proteon Therapeutics, Inc., a publicly traded biotechnology company from 2014 to January 2020. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois. - Garen Bohlin，2010年7月起，他担任我公司董事会成员。2012年5月起，他担任生命科学公司的顾问。2010年1月至2012年4月，他担任生物制药公司Constellation Pharmaceuticals, Inc.的执行副总裁。加入Constellation Pharmaceuticals之前，2005至2009年12月，他担任生物制药公司Sirtris Pharmaceuticals的首席运营官。1999至2008年12月，他担任生物制药公司Syntonix Pharmaceuticals, Inc.的创始首席执行官。在他职业生涯早期，他在生物技术公司Genetics Institute担任多个执行官职位并且是公共会计与咨询公司Arthur Andersen & Co。的合伙人。2005年起，他担任私人生物技术公司Acusphere, Inc.的董事会成员， 该公司曾是上市公司。他目前是私人公司Precision Dermatology, Inc.和上市公司Karyopharm Therapeutics, Inc.的董事会成员。2005至2007年，他担任生物制药公司Praecis Pharmaceuticals, Inc.的董事会成员，该公司曾是上市公司，现在属于葛兰素史克（GlaxoSmithKline）；2007至2009年，担任Targanta Therapeutics, Inc.的董事会成员，该公司曾是上市生物制药公司，现在属于The Medicines Company；2010至2013年担任私人公司SpringLeaf Therapeutics, Inc.的董事会成员。他在伊利诺伊大学（The University of Illinois）获得会计学和金融系学士学位。
- Garen Bohlin has served as a member of our board of directors since July 2010. Since May 2012 Mr. Bohlin has served on the boards of directors and as a consultant to multiple life sciences companies. From January 2010 until April 2012 he served as Executive Vice President of Constellation Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, Inc., a biotechnology company, from 2006 to December 2009. Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals, Inc., a biopharmaceutical company, from 1999 through December 2005. Earlier in his career, he held multiple executive positions at Genetics Institute, Inc., a biotechnology company, and was a partner at Arthur Andersen & Co., a public accounting and consulting organization. Mr. Bohlin currently serves on the board of directors of Collegium Pharmaceutical, Inc. and Karyopharm Therapeutics, Inc., both publicly traded biotechnology companies. He also served on the board of directors for Acusphere, Inc., a specialty pharmaceutical company that was a publicly traded company, from 2005 to 2014; SpringLeaf Therapeutics, Inc., a private biotechnology company, from 2010 to 2013; Precision Dermatology, Inc., a private dermatology company from 2012 to 2014; and Proteon Therapeutics, Inc., a publicly traded biotechnology company from 2014 to January 2020. Mr. Bohlin received his B.S. in accounting and finance from The University of Illinois.
- Gerri Henwood
-
Gerri Henwood，2008年Baudax Bio, Inc.成立起，她担任Baudax Bio, Inc.的总裁、首席执行官和董事。 2006至2013年，她担任MCG的总裁。她继续在MCG为其他公司服务，包括从事其他药物产品开发和商业化的公司。在此之前，她担任自己于1999年底成立的Auxilium Pharmaceuticals, Inc.， 又称Auxilium的总裁和首席执行官。1985至1999年，她担任合同研究组织IBAH, Inc.， 又称IBAH的创始人和首席执行官。1998年被Omnicare收购之前，IBAH净收入达到1亿5千万美元，在纳斯达克上市。她在Smith Kline & French， 现在属于GlaxoSmithKline plc的药物管理项目中开始职业生涯。她从基层爬到品牌经理位置，后担任美国业务的法规和医疗事务主管，后担任国际药物部门营销董事。她是全球生物制药公司Alkermes plc和两家私人公司的董事会成员。她在Neumann University获得生物学学士学位。
Gerri Henwood,has served as Baudax Bio, Inc. President and Chief Executive Officer and a director of the Company since 2019. Ms. Henwood previously served as the President and Chief Executive Officer of Societal CDMO, Inc. ("Societal CDMO") (f/k/a Recro Pharma, Inc.), which she founded in 2008, until 2020. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., a pharmaceutical incubator and consulting firm. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., a contract research organization. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director — Marketing in the International Pharmaceutical Division. Ms. Henwood previously served on the board of directors of Societal CDMO from 2008 until January 2022, and Tetraphase Pharmaceuticals, Inc., a position she held from May 2015 until the first half of 2020. Ms. Henwood also served on the compensation committee of Tetraphase Pharmaceuticals, Inc. She served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood holds a B.S. in Biology from Neumann University. - Gerri Henwood，2008年Baudax Bio, Inc.成立起，她担任Baudax Bio, Inc.的总裁、首席执行官和董事。 2006至2013年，她担任MCG的总裁。她继续在MCG为其他公司服务，包括从事其他药物产品开发和商业化的公司。在此之前，她担任自己于1999年底成立的Auxilium Pharmaceuticals, Inc.， 又称Auxilium的总裁和首席执行官。1985至1999年，她担任合同研究组织IBAH, Inc.， 又称IBAH的创始人和首席执行官。1998年被Omnicare收购之前，IBAH净收入达到1亿5千万美元，在纳斯达克上市。她在Smith Kline & French， 现在属于GlaxoSmithKline plc的药物管理项目中开始职业生涯。她从基层爬到品牌经理位置，后担任美国业务的法规和医疗事务主管，后担任国际药物部门营销董事。她是全球生物制药公司Alkermes plc和两家私人公司的董事会成员。她在Neumann University获得生物学学士学位。
- Gerri Henwood,has served as Baudax Bio, Inc. President and Chief Executive Officer and a director of the Company since 2019. Ms. Henwood previously served as the President and Chief Executive Officer of Societal CDMO, Inc. ("Societal CDMO") (f/k/a Recro Pharma, Inc.), which she founded in 2008, until 2020. From 2006 to 2013, Ms. Henwood served as the President of Malvern Consulting Group, Inc., a pharmaceutical incubator and consulting firm. From 1999 to 2006, Ms. Henwood was the President and Chief Executive Officer of Auxilium Pharmaceuticals, Inc., a biopharmaceutical company she founded in late 1999. From 1985 to 1999, Ms. Henwood was the founder and Chief Executive Officer of IBAH, Inc., a contract research organization. Ms. Henwood began her career with Smith Kline & French, now part of GlaxoSmithKline plc. She rose through the ranks to be a brand manager, then the head of Regulatory and Medical Affairs for the U.S. business and then to the position of Group Director — Marketing in the International Pharmaceutical Division. Ms. Henwood previously served on the board of directors of Societal CDMO from 2008 until January 2022, and Tetraphase Pharmaceuticals, Inc., a position she held from May 2015 until the first half of 2020. Ms. Henwood also served on the compensation committee of Tetraphase Pharmaceuticals, Inc. She served on the board of directors of Alkermes, Inc. and its successor company, Alkermes, plc, a global biopharmaceutical company, from 2003 until March 2015, and on the board of directors of MAP Pharmaceuticals, Inc., a biopharmaceutical company, from 2004 until its acquisition by Allergan, Inc. in March 2013. Ms. Henwood holds a B.S. in Biology from Neumann University.
- Nancy Wysenski
-
Nancy Wysenski，2014年3月起，她担任我公司董事会成员。2009年12月至2012年6月，她担任上市制药公司Vertex Pharmaceuticals Incorporated的执行副总裁和首席商务官。加入Vertex之前，她担任Endo Pharmaceuticals的首席运营官，该公司是有1200员工的专业制药公司，她领导销售、营销、商业运营、供应链管理、人力资源和多个商业发展领域。加入Endo之前，她参与了EMD Pharmaceuticals, Inc.的创立，担任多个领导职位，包括2001至2006年担任总裁和首席执行官，1999至2001年担任商务副总裁。1984至1998年，她在大型制药公司担任销售职位，包括Astra Merck, Inc.的现场销售副总裁。她是上市生物制药公司Alkermes plc的董事和私人公司Reata Pharmaceuticals, Inc.的董事。她是医疗保健商业女性协会研究三角园分会（Research Triangle Park Chapter of the Healthcare Businesswomen’s Association）的创始人，并担任医疗保健商业女性协会提名委员会和全国咨询委员会成员。她在肯特州立大学（Kent State University）获得护理学士学位，在鲍德温·华莱士学院（Baldwin-Wallace College）获得工商管理学硕士学位。
Nancy Wysenski joined our board of directors in May 2020. She served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski has served as a member of the board of directors of Alkermes plc and Cytokinetics Inc. since 2013 and 2020 respectively. Ms. Wysenski formerly served as a director on the board of Tetraphase Pharmaceuticals Inc. from 2014 to 2020 Dova Pharmaceuticals, Inc. from 2018 to 2019 and Inovio Pharmaceuticals, Inc. from 2015 to 2017. She is a founder of the Research Triangle Park chapter of the Healthcare Businesswomen's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association. - Nancy Wysenski，2014年3月起，她担任我公司董事会成员。2009年12月至2012年6月，她担任上市制药公司Vertex Pharmaceuticals Incorporated的执行副总裁和首席商务官。加入Vertex之前，她担任Endo Pharmaceuticals的首席运营官，该公司是有1200员工的专业制药公司，她领导销售、营销、商业运营、供应链管理、人力资源和多个商业发展领域。加入Endo之前，她参与了EMD Pharmaceuticals, Inc.的创立，担任多个领导职位，包括2001至2006年担任总裁和首席执行官，1999至2001年担任商务副总裁。1984至1998年，她在大型制药公司担任销售职位，包括Astra Merck, Inc.的现场销售副总裁。她是上市生物制药公司Alkermes plc的董事和私人公司Reata Pharmaceuticals, Inc.的董事。她是医疗保健商业女性协会研究三角园分会（Research Triangle Park Chapter of the Healthcare Businesswomen’s Association）的创始人，并担任医疗保健商业女性协会提名委员会和全国咨询委员会成员。她在肯特州立大学（Kent State University）获得护理学士学位，在鲍德温·华莱士学院（Baldwin-Wallace College）获得工商管理学硕士学位。
- Nancy Wysenski joined our board of directors in May 2020. She served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998 Ms. Wysenski held several sales focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski has served as a member of the board of directors of Alkermes plc and Cytokinetics Inc. since 2013 and 2020 respectively. Ms. Wysenski formerly served as a director on the board of Tetraphase Pharmaceuticals Inc. from 2014 to 2020 Dova Pharmaceuticals, Inc. from 2018 to 2019 and Inovio Pharmaceuticals, Inc. from 2015 to 2017. She is a founder of the Research Triangle Park chapter of the Healthcare Businesswomen's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association.
高管简历
中英对照 | 中文 | 英文- Maria Stahl
Maria Stahl自2015年3月起担任我们的高级副总裁兼总法律顾问。在加入Tetraphase之前， 2010年10月至2014年8月，Stahl女士曾担任Idenix Pharmaceuticals, Inc.（一家上市的生物技术公司，直到被Merck & Co。收购）的高级副总裁兼总法律顾问。2008年2月至2009年11月，Stahl 女士担任Idenix的副总裁，副总法律顾问，并于2007年2月至2008年2月担任助理总顾问。在加入Idenix之前，2009年11月至2010年10月，Stahl女士 担任Zipcar, Inc.（一家汽车共享公司）的总顾问。2005年2月至2007年2月，Stahl女士担任 Capital Crossing Bank的副总裁兼公司法律顾问。 在此之前，Stahl女士在Wilmer Cutler Pickering Hale和Dorr LLP任职。 Stahl女士获得 Providence College的文学士学位和 Yale Law School的法学博士学位。
Maria Stahl has served as our Chief Business Officer and General Counsel since June 2019 and served Senior Vice President and General Counsel from March 2015 to June 2019. Prior to joining Tetraphase, Ms. Stahl served as Senior Vice President, General Counsel of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company until its acquisition by Merck & Co., from October 2010 to August 2014. Ms. Stahl received a B.A. from Providence College and a J.D. from Yale Law School.- Maria Stahl自2015年3月起担任我们的高级副总裁兼总法律顾问。在加入Tetraphase之前， 2010年10月至2014年8月，Stahl女士曾担任Idenix Pharmaceuticals, Inc.（一家上市的生物技术公司，直到被Merck & Co。收购）的高级副总裁兼总法律顾问。2008年2月至2009年11月，Stahl 女士担任Idenix的副总裁，副总法律顾问，并于2007年2月至2008年2月担任助理总顾问。在加入Idenix之前，2009年11月至2010年10月，Stahl女士 担任Zipcar, Inc.（一家汽车共享公司）的总顾问。2005年2月至2007年2月，Stahl女士担任 Capital Crossing Bank的副总裁兼公司法律顾问。 在此之前，Stahl女士在Wilmer Cutler Pickering Hale和Dorr LLP任职。 Stahl女士获得 Providence College的文学士学位和 Yale Law School的法学博士学位。
- Maria Stahl has served as our Chief Business Officer and General Counsel since June 2019 and served Senior Vice President and General Counsel from March 2015 to June 2019. Prior to joining Tetraphase, Ms. Stahl served as Senior Vice President, General Counsel of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company until its acquisition by Merck & Co., from October 2010 to August 2014. Ms. Stahl received a B.A. from Providence College and a J.D. from Yale Law School.
- Christopher Watt
Christopher Watt自2017年1月起担任我们的高级副总裁，财务。他此前曾担任我们的财务Vice President（2015年7月至2017年1月）。在加入Tetraphase之前，Watt先生在Biogen，Inc.（一家公开上市的制药公司）工作了十年，最近担任全球商业金融高级总监。Watt先生从2009年到2011年担任Biogen’；S UK/Ireland Affiliate的财务总监，从2006年到2009年担任国际业务规划总监。在加入Biogen之前，Watt先生在Intersystems Corporation，Putnam Investments，Procter and Gamble和Shawmut Bank担任了15年的各种财务职务。Mr.Watt在Colby College获得学士学位，在University of Michigan获得工商管理硕士学位。
Christopher Watt has served as our Senior Vice President, Finance since January 2017. He previously served as our Vice President, Finance from July 2015 to January 2017. Prior to joining Tetraphase, Mr. Watt spent ten years at Biogen, Inc., a publicly traded pharmaceutical company, most recently serving as Senior Director, Global Commercial Finance. From 2009 to 2011 Mr. Watt served as the Finance Director for Biogen’s UK/Ireland affiliate and from 2006 to 2009 as Director of Business Planning, International. Prior to Biogen, Mr. Watt spent fifteen years in various financial roles at InterSystems Corporation, Putnam Investments, Procter and Gamble and Shawmut Bank. Mr. Watt received a B.A. from Colby College and an M.B.A. from the University of Michigan.- Christopher Watt自2017年1月起担任我们的高级副总裁，财务。他此前曾担任我们的财务Vice President（2015年7月至2017年1月）。在加入Tetraphase之前，Watt先生在Biogen，Inc.（一家公开上市的制药公司）工作了十年，最近担任全球商业金融高级总监。Watt先生从2009年到2011年担任Biogen’；S UK/Ireland Affiliate的财务总监，从2006年到2009年担任国际业务规划总监。在加入Biogen之前，Watt先生在Intersystems Corporation，Putnam Investments，Procter and Gamble和Shawmut Bank担任了15年的各种财务职务。Mr.Watt在Colby College获得学士学位，在University of Michigan获得工商管理硕士学位。
- Christopher Watt has served as our Senior Vice President, Finance since January 2017. He previously served as our Vice President, Finance from July 2015 to January 2017. Prior to joining Tetraphase, Mr. Watt spent ten years at Biogen, Inc., a publicly traded pharmaceutical company, most recently serving as Senior Director, Global Commercial Finance. From 2009 to 2011 Mr. Watt served as the Finance Director for Biogen’s UK/Ireland affiliate and from 2006 to 2009 as Director of Business Planning, International. Prior to Biogen, Mr. Watt spent fifteen years in various financial roles at InterSystems Corporation, Putnam Investments, Procter and Gamble and Shawmut Bank. Mr. Watt received a B.A. from Colby College and an M.B.A. from the University of Michigan.
- Larry Edwards
Larry Edwards，他一直担任董事、总裁和首席执行官（2020年以来）。从2015年到2020年，他担任Tetraphase Pharmaceuticals, Inc.的多个职位，最近担任首席执行官。从2014年到2015年，他担任Cubist Pharmaceuticals, Inc.（被Merck & Co.， Inc.收购）的革兰氏阴性特许经营权的高级营销总监。从1999年到2014年，他曾担任Merck and Co.,Inc.的多个职位，最近担任艰难梭菌和新传染病产品的全球营销总监。他获得俄亥俄大学（Ohio University）的商业和医疗管理学士学位。
Larry Edwards has served as a director, President and Chief Executive Officer since 2020. From 2015 to 2020 he served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015 Mr. Edwards served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc.. From 1999 to 2014 he served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.- Larry Edwards，他一直担任董事、总裁和首席执行官（2020年以来）。从2015年到2020年，他担任Tetraphase Pharmaceuticals, Inc.的多个职位，最近担任首席执行官。从2014年到2015年，他担任Cubist Pharmaceuticals, Inc.（被Merck & Co.， Inc.收购）的革兰氏阴性特许经营权的高级营销总监。从1999年到2014年，他曾担任Merck and Co.,Inc.的多个职位，最近担任艰难梭菌和新传染病产品的全球营销总监。他获得俄亥俄大学（Ohio University）的商业和医疗管理学士学位。
- Larry Edwards has served as a director, President and Chief Executive Officer since 2020. From 2015 to 2020 he served in various positions at Tetraphase Pharmaceuticals, Inc., most recently serving as Chief Executive Officer. From 2014 to 2015 Mr. Edwards served as Senior Director of Marketing of the Gram-negative Franchise of Cubist Pharmaceuticals, Inc. acquired by Merck & Co., Inc.. From 1999 to 2014 he served in various positions at Merck and Co., Inc., most recently serving as Global Marketing Director of Clostridium Difficile and New Infectious Disease Products. Mr. Edwards received a B.S. degree in business and healthcare administration from Ohio University.